14-10-2020 | Gastroenterology | Video
UEGW 2020 | Ozanimod maintains remission in patients with ulcerative colitis
Silvio Danese outlines the 52-week TRUE NORTH study findings showing the benefits of ozanimod in patients with moderate-to-severe ulcerative colitis (4:11).
Funding for independent interviews at UEG Week Virtual 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.